Since its initial approval in 2001, imatinib revolutionized the treatment paradigm of chronic myeloid leukemia (CML). By specifically targeting the underlying genetic driver of CML - the BCR-ABL fusion oncogene - imatinib ushered in a new era of precision oncology. However, challenges emerged as some patients saw their disease progress due resistance caused by mutations within the BCR-ABL gene...